The paediatric dosage form of benznidazole will be manufactured by LAFEPE.
LAFEPE will make paediatric benznidazole available at cost to all public health institutions.
The paediatric dosage form of benznidazole was officially granted registration in late 2011 by the
National Health Surveillance Agency (ANVISA) of Brazil. DNDi is working with LAFEPE to register the drug
in other Chagas disease‐endemic countries, including Argentina, Bolivia, Colombia, and Paraguay.
Additional Tools to Facilitate Implementation and Access
- Demand Forecast: a guide to help national Chagas control programmes and others gauge demand for benznidazole.
- Procurement Guide: step‐by‐step instructions for countries to order the paediatric dosage form of benznidazole from LAFEPE.
- Tool Box: education, communication, and training materials to help in implementation of the paediatric dosage form of benznidazole in the field. The Tool Box contains key information for health professionals, patients, and mothers and caregivers to promote correct and safe administration of the drug, including treatment guidelines, leaflets, posters, photographs, a flip chart, and a dosing table.